UMN Pharma Inc. (headquartered in Akita, President & CEO: Shuichi Kanazashi) today announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine. Trials will begin in mid-June followed by the completion of necessary investigations for an IND filing as required by the PMDA (Pharmaceutical and Medical Devices Agency) based onPharmaceutical Affairs Law. The purpose of this clinical study is to assess safety, efficacy and appropriate dose for the IND product in healthy adults aged 20-40.